ArticleJournal of nanobiotechnology2026
Biomimetic nanoplatforms modulating mitochondrial pathways in IVDD.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveTo develop and evaluate a mitochondria-targeted biomimetic nanoplatform (nMitoQ-SNA-CMT) for the treatment of intervertebral disc degeneration (IVDD).
methodsA rat IVDD model and an H
resultsnMitoQ-SNA-CMT efficiently targeted mitochondria, scavenged excessive reactive oxygen species (ROS), and silenced miR-141-3p, thereby activating SESN2-dependent UPRmt and mitophagy. This dual action markedly reduced mitochondrial DNA release and suppressed cGAS-STING pathway activation, leading to attenuation of NPC senescence, inflammatory responses, and extracellular matrix degradation. In IVDD rat models, nMitoQ-SNA-CMT significantly restored disc structure and function and outperformed free MitoQ and non-coated nanoparticles.
conclusionnMitoQ-SNA-CMT represents a potent and safe therapeutic strategy for IVDD by coordinately regulating mitochondrial oxidative stress, mitophagy, and innate immune activation, providing a promising platform for precision nanomedicine in degenerative disc diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.